Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer
M Yoshimoto, S Takao, M Hirata, Y Okamoto… - Cancer chemotherapy …, 2012 - Springer
Purpose Metronomic combination chemotherapy with the oral fluoropyrimidine
doxifluridine/5′-deoxy-5-fluorouridine (5-DFUR) and oral cyclophosphamide (C) showed …
doxifluridine/5′-deoxy-5-fluorouridine (5-DFUR) and oral cyclophosphamide (C) showed …
[HTML][HTML] Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients
Abstract Background Cancer stem cells (CSCs) are epithelial tumor cells that express
CD44+ CD24-/lo. CSCs can be further divided into those that have aldehyde …
CD44+ CD24-/lo. CSCs can be further divided into those that have aldehyde …
The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy
P Wimberger, JU Blohmer, P Krabisch, T Link… - Breast Cancer …, 2023 - Springer
Abstract Background Disseminated tumor cells (DTCs) in the bone marrow are observed in
about 40% at primary diagnosis of breast cancer and predict poor survival. While anti …
about 40% at primary diagnosis of breast cancer and predict poor survival. While anti …
DTCs in breast cancer: clinical research and practice
W Janni, B Rack, N Kasprowicz, C Scholz… - … Residual Disease and …, 2012 - Springer
Minimal residual disease (MRD), ie, isolated tumor cells (ITC) in bone marrow, may be the
source of potentially fatal overt distant metastases in solid tumors even years after primary …
source of potentially fatal overt distant metastases in solid tumors even years after primary …
Prognostic value of disseminated tumor cells in the bone marrow of patients with operable primary breast cancer: a long-term follow-up study
C Domschke, IJ Diel, S Englert, S Kalteisen… - Annals of surgical …, 2013 - Springer
Background Detection of disseminated tumor cells (DTC) in primary breast cancer (BC)
patients' bone marrow (BM) seems to be a surrogate marker of tumor spread and an …
patients' bone marrow (BM) seems to be a surrogate marker of tumor spread and an …
Disseminated tumor cells in the bone marrow of patients with operable primary breast cancer: prognostic impact in immunophenotypic subgroups and clinical …
S Stefanovic, I Diel, P Sinn, S Englert… - Annals of surgical …, 2016 - Springer
Background Disseminated tumor cells (DTC) in the bone marrow (BM) of primary breast
cancer (BC) patients are a promising surrogate marker of micrometastatic spread and an …
cancer (BC) patients are a promising surrogate marker of micrometastatic spread and an …
Disseminated tumor cells predict survival after neoadjuvant therapy in primary breast cancer
C Hall, S Krishnamurthy, A Lodhi, A Bhattacharyya… - Cancer, 2012 - Wiley Online Library
BACKGROUND: Tumor cells that disseminate to the bone marrow (disseminated tumor cells
[DTCs]) have been identified in 30% of patients with stage I through II breast cancer (BC) …
[DTCs]) have been identified in 30% of patients with stage I through II breast cancer (BC) …
Effects of rat bone marrow‑derived mesenchymal stem cells on breast cancer cells with differing hormone receptor status
Y Wang, S Shao, M Luo, S Huang… - Oncology …, 2017 - spandidos-publications.com
Breast cancer is a heterogeneous disease that can be classified into several molecular
intrinsic subtypes according to hormone markers, including estrogen receptor, progesterone …
intrinsic subtypes according to hormone markers, including estrogen receptor, progesterone …
Invasive lobular carcinoma predicts micrometastasis in breast cancer
SM Gainer, AK Lodhi, A Bhattacharyya… - Journal of Surgical …, 2012 - Elsevier
BACKGROUND: Invasive lobular carcinomas (ILCs) are almost always estrogen receptor
(ER) positive. Most delayed breast cancer recurrences occur in ER-positive patients …
(ER) positive. Most delayed breast cancer recurrences occur in ER-positive patients …
Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on …
M Synnestvedt, E Borgen, E Schlichting… - Breast cancer research …, 2013 - Springer
Detection of disseminated tumour cells (DTCs) in bone marrow by immunocytochemistry
(ICC) includes morphological evaluation of cytokeratin immunopositive cells. The aim of this …
(ICC) includes morphological evaluation of cytokeratin immunopositive cells. The aim of this …